China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its subsidiary Xuanzhu Biopharmaceutical Co., Ltd has received approval to proceed with a Phase II clinical study of anaprazole for the treatment of reflux esophagitis (RE) and associated symptoms, including acid reflux, heartburn, and retrosternal pain.
Drug Profile
Anaprazole, the only homegrown proton pump inhibitor (PPI) in China, was first submitted for marketing in 2021 for duodenal ulcer treatment. The drug’s unique metabolism—both enzymatic and nonenzymatic—reduces the risk of drug-drug interactions. Clinical trials have shown anaprazole’s potential for best-in-class safety and symptom relief.
Clinical Trial Details
The Phase II study will evaluate anaprazole’s efficacy in treating RE and managing related symptoms. The drug’s dual metabolic pathways and strong safety profile position it as a promising therapy for gastrointestinal disorders.-Fineline Info & Tech
